EarlySight Secures CHF 6.1 Million to Advance Vision-Saving Technology

EarlySight, a Geneva-based startup, is excited to announce the successful extension of its Seed round to CHF 6.1 million, with Zürcher Kantonalbank joining its strong syndicate of investors, which includes Verve Ventures, Nina Capital, NovaCapital, and CADFEM International GmbH.

This new funding marks a significant milestone in its mission to transform retinal diagnostics. It will enable the startup to accelerate our pathway toward U.S. regulatory approval, launch its second-generation Cellularis® platform, and deepen its commercial collaborations worldwide.

Transforming Retinal Diagnostics

Millions of people worldwide suffer from retinal diseases such as age-related macular degeneration (AMD), one of the leading causes of vision loss. Traditional diagnostic tools often detect these conditions only after irreversible damage has occurred.
EarlySight’s AI-powered Cellularis® technology provides imaging at the cellular level, enabling ophthalmologists to detect diseases much earlier and improve treatment outcomes.

With over 1,000 patients scanned and 18,000+ retinal images analyzed, the solution is already trusted by leading clinical and research institutions.

“This funding round marks a pivotal moment for EarlySight. With the support of our investors and new board members, we’re scaling up to bring vision-saving technology to millions.”
— Timothé Laforest, CEO of EarlySight

Growing Leadership Team

Alongside this financing, we are thrilled to welcome new members to our Board of Directors, who bring invaluable expertise in healthcare and technology:

• Peter Aggersbjerg, Vice-Chairman of the Board:
  “EarlySight is pushing the boundaries of eye care with cutting-edge technology that enables earlier and more precise detection of retinal diseases. It’s inspiring to be part of a team so deeply committed to improving vision health globally.”

• Andy Weymann, MD MBA, Independent Director:
  “EarlySight’s Cellularis® technology enables ophthalmologists to diagnose retinal diseases like AMD much earlier, leading to better outcomes for millions of patients. I’m looking forward to supporting this mission to preserve sight.”

• Prof. Francine Behar-Cohen, Co-founder and Medical Advisor:
  “Cellularis® offers clinicians an unprecedented view of the pigment epithelium layer, where most retinal diseases originate. This precision will enable earlier detection, preventive treatment, and ultimately, better patient care.”

Looking Ahead

The extension of its Seed round gives EarlySight the resources to scale globally and accelerate clinical validation, bringing groundbreaking technology to eye clinics and hospitals.
The company is one step closer to a future where early detection saves vision, and millions of people can maintain their independence and quality of life.

➡️ Source: Press Release | 📸 © Earlysight